Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2001-06-22
2002-07-16
Henley, III, Raymond (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
06420416
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to a method for treatment of brain injury and neuronal disorders, such as epilepsy, by administration of an effective amount of nefiracetam.
2. Discussion of the Background
Traumatic brain injury, as well as neuronal disorders with common pathological features, such as stroke and epilepsy, can have devastating effects on a person, both short-term and long-term. Traumatic brain injury is often associated with cerebral concussion. Cerebral concussion is a traumatically induced derangement of the nervous system, characterized clinically by immediate and transient impairment of consciousness and is generally not associated with remarkable gross anatomical changes. Even moderate levels of concussive human head injury, not requiring prolonged hospitalization, can result in persistent neurological disturbances often lasting for months. These disturbances often include dizziness and balance problems, and fine motor skill dysfunction. Lyeth et al,
Brain Research,
452, 39-48 (1988).
Traumatic brain injury is known to be a biphasic process. The first phase, the excitatory phase, occurs immediately upon injury. During this phase there is great neuronal excitation due to the trauma. Following the excitatory phase is the recovery phase, during which the neuronal excitation has abated and the job of repair has begun. Most often with traumatic brain injury, the excitatory phase is associated with increased intracranial pressure (ICP), with fluctuations of ICP over several days or more. Patients in the excitatory phase must typically be cared for in the intensive care unit of a hospital. Once the ICP has been stabilized and the patient can be removed from intensive care, the patient is typically entering into the recovery phase.
Traumatic brain injury produces an acute neuronal depolarization and an extensive release of neurotransmitters. The resulting excessive receptor activation may produce abnormal neurotransmitter-receptor interactions which contribute to the pathophysiology associated with experimental traumatic brain injury. Both the cholinergic and glutamatergic receptor systems have been documented to play a prominent role in the receptor-mediated pathophysiology of traumatic brain injury. Prior attempts to treat traumatic brain injury have focused on administration of antagonists of these cholinergic or glutamatergic receptors (such as the AMPA-glutamate receptor, wherein AMPA represents &agr;-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) as early as possible after the occurrence of the injury. (See Hamm et al,
Cognitive Brain Research,
1, 223-226 (1993) and Lyeth et al,
Brain Research,
452, 39-48 (1988)). The goal of these studies was to add the antagonist during the excitatory phase of the injury process during the period of high receptor activity in an attempt to minimize the damage occurring to the neuronal tissue. Unfortunately, such attempts were not successful.
SUMMARY OF THE INVENTION
Accordingly, one object of the present invention is to provide a method effective for the treatment of brain injuries, particularly traumatic brain injury.
A further object of the present invention is to provide a method for treatment of neuronal disorders such as epilepsy.
These and other objects of the present invention have been satisfied by the discovery of a method for the treatment of neuronal disorders and brain injury comprising:
administering to a subject in need thereof, an effective amount of nefiracetam.
REFERENCES:
patent: 5461157 (1995-10-01), Kamihara et al.
patent: 5886023 (1999-03-01), Otomo et al.
patent: 6107330 (2000-08-01), Nabeshima et al.
patent: WO 00/07593 (2000-02-01), None
Berlow (ed.), The Merck Manual, Published by Merck & Company (NJ), pp. 1305-1307) (1982).
Abstract from the 17thannual meeting of the Japan Neuroscience Society, Nagoya, Japan, Dec. 7-9, 1993, 2 pp.
Brian R. Pike, et al., “Effect of Tetrahydroaminoacridine, a Cholinesterase Inhibitor, on Cognitive Performance Following Experimental Brain Injury”, Journal of Neurotrauma, vol. 14, No. 12, pp. 897-905, 1997.
Kiyofumi Yamada, et al., “Nefiracetam (DM-9384): A Novel Antiamnesic Drug”, CNS Drug Reviews, vol. 2, No. 3, pp. 322-342, 1996.
Robert J. Hamm, et al., “Cognitive impairment following traumatic brain injury: the effect of pre- and post-injury administration of scopolamine and MK-801”, Cognitive Brain Research, vol. 1, pp. 223-226, 1993.
B.G. Lyeth, et al., “Effects of scopolamine treatment on long-term behavioral deficits following concussive brain injury to the rat”, Brain Research, vol. 452, pp. 39-48, 1988.
Deford S. Michelle
Hamm Robert
Shiotani Tadashi
Daiichi Pharmaceutical Co. Ltd.
Henley III Raymond
Oblon & Spivak, McClelland, Maier & Neustadt P.C.
LandOfFree
Method of treating epilepsy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating epilepsy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating epilepsy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2820345